Entero Healthcare Solutions Limited announced the outcome of its Board Meeting held on June 11, 2026, confirming two primary corporate actions. The Board of Directors approved the allotment of 3,420 equity shares (face value of Rs. 10 each) to an eligible employee following the exercise of options under the Entero Employee Stock Option Plan 2023. Additionally, the Board noted the grant of 17,500 fresh employee stock options under the same 2023 plan, in compliance with SEBI regulations.

Entero Healthcare Solutions Limited, headquartered in Gurugram, Haryana, is a technology-driven, integrated healthcare product distribution platform founded in 2018. The company provides comprehensive distribution and data analytics solutions to healthcare manufacturers while acting as a one-stop procurement hub for pharmacies, hospitals, and clinics across India. During 2025, the company actively pursued inorganic growth through the acquisition of stakes in entities such as Peerless Biotech Private Limited and entered into share purchase agreements to expand its subsidiary network. The company also underwent organizational restructuring by transferring shares of its wholly-owned subsidiaries, CPD Pharma Private Limited and Chethana Pharma Distributors Private Limited, to Rada Medisolutions Private Limited.

In the quarter ended September 30, 2025, the company reported revenue from operations of 4,086.70 million. Financial data from that period indicates a complex operational landscape, including impairment losses related to loans given to subsidiaries and significant investments in Optionally Convertible Debentures (OCDs) of various healthcare service providers. As a publicly listed entity, the company continues to engage with various institutional investors to support its integrated healthcare ecosystem.